Patents by Inventor Hong Mimi Zhou

Hong Mimi Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA binding agents and uses thereof
    Patent number: 11746157
    Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: September 5, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
  • ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD79B ANTIBODIES
    Publication number: 20230094867
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a CD9B441 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include CD9B441.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Katharine D. Grugan, Christian R. Martinez, Nan Wei, Hong Mimi Zhou
  • PSMA BINDING AGENTS AND USES THEREOF
    Publication number: 20200024360
    Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: May 21, 2019
    Publication date: January 23, 2020
    Inventors: Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8999333
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8951525
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 10, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • HUMAN TISSUE FACTOR ANTIBODY AND USES THEREOF
    Publication number: 20140234304
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Juan Carlos ALMAGRO, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8722044
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20130189250
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 25, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Engineered anti-IL-13 antibodies, compositions, methods and uses
    Patent number: 8399630
    Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: March 19, 2013
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
  • Engineered anti-IL-13 antibodies, compositions, methods and uses
    Patent number: 8323646
    Abstract: The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Grant
    Filed: August 12, 2009
    Date of Patent: December 4, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiging Feng
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20120237528
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES
    Publication number: 20120045438
    Abstract: The present invention relates to engineered antibodies immuno specific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 23, 2012
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov, Yiqing Feng
  • ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES
    Publication number: 20100111959
    Abstract: The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications.
    Type: Application
    Filed: August 12, 2009
    Publication date: May 6, 2010
    Inventors: Ronald V. Swanson, Ellen Chi, Gopalan Raghunathan, Shanrong Zhao, Johan Fransson, Wendy Cordier, Hong Mimi Zhou, Juan C. Almagro, Linus Hyun, Jill Giles-Komar, Karyn T. O'Neil, Jill M. Carton, Alexey V. Teplyakov